Unknown

Dataset Information

0

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer.


ABSTRACT: PURPOSE:The conversion of tumor cells from an epithelial to a mesenchymal-like phenotype, via a process designated as the epithelial-mesenchymal transition (EMT), is known to mediate tumor resistance to a variety of cell death inducers, including cytotoxic effector immune cells. The goal of this study was to identify and potentially repurpose FDA-approved compounds capable of reducing mesenchymal features of human lung carcinoma cells, which could be used in combination with immunotherapies or chemotherapeutic strategies to improve clinical responses. EXPERIMENTAL DESIGN:In the current report, we have utilized a quantitative high-throughput screening (qHTS) of a pharmaceutical collection of more than 2,000 compounds to identify clinically approved drugs capable of augmenting the sensitivity of mesenchymal-like, lung cancer cells to immune- and chemotherapy-mediated lysis, both in vitro and in vivo RESULTS: The estrogen receptor antagonist fulvestrant was shown to reduce mesenchymal features of lung carcinoma cells, resulting in tumor sensitization to the cytotoxic effect of antigen-specific T cells, natural killer (NK) effector cells, and chemotherapy both in vivo and in vitro CONCLUSIONS: To our knowledge, this is the first report defining a potential role for estrogenic signaling in promoting tumor resistance to immune-mediated cytotoxicity and chemotherapy in lung cancer. Our data demonstrate a robust association between the acquisition of mesenchymal attributes, therapeutic resistance of lung carcinoma cells, and the expression of estrogen receptor 1 (ESR1), supporting further investigations on the role of estrogen signaling in lung cancer progression via the induction of EMT. Clin Cancer Res; 22(24); 6204-16. ©2016 AACR.

SUBMITTER: Hamilton DH 

PROVIDER: S-EPMC5143224 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer.

Hamilton Duane H DH   Griner Lesley Mathews LM   Keller Jonathan M JM   Hu Xin X   Southall Noel N   Marugan Juan J   David Justin M JM   Ferrer Marc M   Palena Claudia C  

Clinical cancer research : an official journal of the American Association for Cancer Research 20160607 24


<h4>Purpose</h4>The conversion of tumor cells from an epithelial to a mesenchymal-like phenotype, via a process designated as the epithelial-mesenchymal transition (EMT), is known to mediate tumor resistance to a variety of cell death inducers, including cytotoxic effector immune cells. The goal of this study was to identify and potentially repurpose FDA-approved compounds capable of reducing mesenchymal features of human lung carcinoma cells, which could be used in combination with immunotherap  ...[more]

Similar Datasets

| S-EPMC7505887 | biostudies-literature
| S-EPMC5059888 | biostudies-literature
2019-10-25 | E-MTAB-8294 | biostudies-arrayexpress
| S-EPMC9613684 | biostudies-literature
| S-EPMC5477582 | biostudies-literature
| S-EPMC2683142 | biostudies-literature
| S-EPMC6176231 | biostudies-literature
| S-EPMC6385031 | biostudies-literature
| S-EPMC6151865 | biostudies-literature
| S-EPMC5760359 | biostudies-literature